Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
6 evidence topics · 7 sources
Oral tablet: phase 3 NOVA-2
| Arm or intervention | Quoted record |
|---|---|
| Experimental arm 1 | “LB-102 (50 mg tablet)” |
| Experimental arm 2 | “LB-102 (100 mg tablet)” |
| Intervention description | “LB-102 oral tablet given for six weeks” |
| Placebo | “Placebo tablet given orally for six weeks” |
Strengths studied: open-label NOVA-3
Oral capsule: phase 1 receptor occupancy study
Strengths studied: phase 1 single and multiple ascending dose study
| Cohort | Quoted record |
|---|---|
| Part A Cohort 1 | “LB-102 50 mg (n=6) or Matching Placebo (n=2) x 1 day” |
| Part A Cohort 2 | “LB-102 15 mg (n=6) or Matching Placebo (n=2) x 1 day” |
| Part A Cohort 3 | “LB-102 100 mg (n=6) or Matching Placebo (n=2) x 1 day” |
| Part A Cohort 4 | “LB-102 200 mg (n=6) or Matching Placebo (n=2) x 1 day” |
| Part A Cohort 5 | “LB-102 150 mg (n=6) or Matching Placebo (n-2) x 1 day” |
| Part B Cohort 6 | “LB-102 50 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)” |
| Part B Cohort 7 | “LB-102 100 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)” |
| Part B Cohort 8 | “LB-102 75 mg (n=6) or Matching Placebo (n=2) BID x 7 days (QD on Day 7)” |
Doses selected to inform commercial use
Commercial dosage form, strengths, and package configurations
No evidence found.